Pulmonx(LUNG)

Search documents
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
zacks.com· 2024-05-22 14:56
Core Viewpoint - Pulmonx Corporation (LUNG) shares have increased by 17.1% recently, with analysts suggesting a potential upside of 80.3% based on a mean price target of $15.83 [1][10]. Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $1.72, indicating variability among analysts [2]. - The lowest price target of $14 suggests a 59.5% increase, while the highest target of $18 indicates a potential surge of 105% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [8]. Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about LUNG's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [10]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 8.7%, with two estimates moving higher and no negative revisions [11]. - LUNG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12].
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
prnewswire.com· 2024-05-16 22:46
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult p ...
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Newsfilter· 2024-05-06 21:03
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the "Compensation Committee") granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to ...
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
Zacks Investment Research· 2024-05-06 14:56
Shares of Pulmonx Corporation (LUNG) have gained 19.2% over the past four weeks to close the last trading session at $9.82, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 56.1%.The average comprises six short-term price targets ranging from a low of $12 to a high of $18, with a standard deviation of $2.34. While the lowest estimate indicat ...
Pulmonx(LUNG) - 2024 Q1 - Quarterly Report
2024-05-03 20:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jur ...
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-05-01 23:05
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.36, delivering a surprise of 7.69%.Over the last four quarters, the company has surpa ...
Pulmonx(LUNG) - 2023 Q4 - Annual Report
2024-02-27 21:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jurisdiction of incorporation or organizati ...
Pulmonx(LUNG) - 2023 Q4 - Earnings Call Presentation
2024-02-22 02:01
© 2024 Pulmonx Corporation1 © 2024 Pulmonx Corporation | --- | --- | --- | --- | |----------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------| | | | | | | Large Market | | | Broadly Reimbursed | | $12B opportunity for severe emphysema | | | In global guidelines & reimbursed in US, Europe and Australia | | | | | | | Precision Treatment | | | Global Footprint | | Proprietary patient selection technology & minimal ...
Pulmonx(LUNG) - 2023 Q3 - Quarterly Report
2023-11-03 20:04
WASHINGTON, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other ...
Pulmonx(LUNG) - 2023 Q2 - Earnings Call Transcript
2023-08-06 06:20
Pulmonx Corporation (NASDAQ:LUNG) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Dorothy Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Corp. Jason Bednar - Piper Sandler Zachary Day - Canaccord Genuity Group Inc. Operator Thank you for standing by. Welcome to the Pulmonx Second Quarter 2023 Earnings Conference Call. At thi ...